Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorARLEGUI, Hugo
dc.contributor.authorBOLLAERTS, K.
dc.contributor.authorBAUCHAU, V.
dc.contributor.authorNACHBAUR, G.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.contributor.authorPRAET, N.
dc.date.accessioned2021-01-13T10:04:53Z
dc.date.available2021-01-13T10:04:53Z
dc.date.issued2020
dc.identifier.issn1179-1942 (Electronic) 0114-5916 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23779
dc.description.abstractEnIntroduction Quantitative benefit-risk models (qBRm) applied to vaccines are increasingly used by public health authorities and pharmaceutical companies as an important tool to help decision makers with supporting benefit-risk assessment (BRA). However, many publications on vaccine qBRm provide insufficient details on the methodological approaches used. Incomplete and/or inadequate qBRm reporting may affect result interpretation and confidence in BRA, highlighting a need for the development of standard reporting guidance. Objectives Our objective was to provide an operational checklist for improved reporting of vaccine qBRm. Methods The consolidated standards of reporting quantitative Benefit-RIsk models applied to VACcines (BRIVAC) were designed as a checklist of key information to report in qBRm scientific publications regarding the assessed vaccines, the methodological considerations and the results and their interpretation. Results In total, 22 items and accompanying definitions, recommendations, explanations and examples were provided and divided into six main sections corresponding to the classic subdivisions of a scientific publication: title and abstract (items 1–2), introduction (items 3–4), methods (items 5–15), results (items 16–17), discussion (items 18–20) and other (items 21–22). Conclusions The BRIVAC checklist is the first initiative providing an operational checklist for improved reporting of qBRm applied to vaccines in scientific articles. It is intended to assist authors, peer-reviewers, editors and readers in their critical appraisal. Future initiatives are needed to provide methodological guidance to perform qBRm while taking into account the vaccine specificities.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subjectPharmacoEpi-Drugs
dc.title.enBenefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
dc.title.alternativeDrug Safen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s40264-020-00982-9en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32918682en_US
bordeaux.journalDrug Safetyen_US
bordeaux.page1105-1120en_US
bordeaux.volume43en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue11en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamHEALTHY_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03166478
hal.version1
hal.date.transferred2021-03-11T11:01:59Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drug%20Safety&rft.date=2020&rft.volume=43&rft.issue=11&rft.spage=1105-1120&rft.epage=1105-1120&rft.eissn=1179-1942%20(Electronic)%200114-5916%20(Linking)&rft.issn=1179-1942%20(Electronic)%200114-5916%20(Linking)&rft.au=ARLEGUI,%20Hugo&BOLLAERTS,%20K.&BAUCHAU,%20V.&NACHBAUR,%20G.&BEGAUD,%20Bernard&rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record